The Only Retatrutide Paperwork This Site Actually Opened

The two files, and who pays for the link

The company that pays this site is Peptara Labs, and its paperwork is the only paperwork opened here. Read the rest of this page with that set first. From files downloaded on 2026-09-01, two documents were pulled and their type confirmed:

• A certificate document for the retatrutide batch, pulled from peptaralabs.io and confirmed as a four-page PDF. Open it here: the retatrutide certificate.
• A second-laboratory report image for the same compound, pulled and confirmed as a PNG measuring 1600 by 2360. Open it here: the second-laboratory report.

Those two are the only files this site opened. The certificates page links fourteen certificate PDFs alongside four second-laboratory reports, and everything past the two above is reported only as published and linked, not as opened.

What the certificate panel covers

The panel covers, as a list because the source is a list: identity by HPLC retention-time matching together with LC-MS, chromatographic purity by HPLC measured against a release criterion of not less than 95.0 percent, net peptide content, sterility, bacterial endotoxin, heavy metals, and a fentanyl immunoassay screen. The heavy metal panel covers arsenic, cadmium, chromium, mercury and lead, and every one of them returned Not Detected on the published batches.

Measured purity across the currently published catalog runs 98.6 to 99.6 percent, which the company's homepage summarises as "99% average purity". That is the company's phrase for its own range, reported here and not recomputed.

The certificate names Titreon Analytical, and Peptara Labs writes that its quality system is aligned to ISO/IEC 17025:2017, not itself accredited. The second half of that phrase stays attached in every mention: the wording places a standard the laboratory follows in the laboratory's own account, and it is not a statement that any outside body assessed the laboratory against the standard.

The second laboratory, cleared

Criterion 01 is a report from a second laboratory, and it is cleared on this record. Janoshik supplies a second-laboratory bacterial endotoxin report on the retatrutide batch, and four such reports are published across the catalog. The four covered batches are retatrutide, tirzepatide, BPC-157 and GHK-Cu, each named here only as a batch that carries a report, and none as a route to obtain anything.

One published mechanism can force a measurement by an outside laboratory. The company states a 60-day money back guarantee: sixty days from delivery to send a vial to an outside laboratory, with a full refund if it does not test as stated on its certificate or if the order was not handled correctly, as set out on its trust page. The limit travels with it: the guarantee covers whether material matched its certificate, and it covers nothing about any person.

The two that came back partly cleared

This is the part that keeps the section from reading as an advertisement. Two criteria did not clear outright.

• Criterion 05, partly cleared. Batch identifiers are published per product, and the retatrutide card shows a batch code alongside a June 2026 test date. The vials ship unlabeled by design, so nothing on the received unit carries the code, and the published route from unit back to certificate runs through the company's support channel using the order number. The batch is identified on the document. The unit is not marked. That gap is why the cell reads partly cleared and not cleared.
• Criterion 06, partly cleared. The second-laboratory reports carry a unique verification key, and Peptara Labs states the key can be checked at janoshik.com/verify. This site did not reach that address on 2026-09-01 and does not link it. The route is stated by the supplier and was not tested here, so it is reported as a stated route and not as a completed check.

Both partly cleared cells trace back to the same two criteria set out under the two criteria that came back partly cleared.

Two closers, and the arrangement

Fourteen of sixteen products carry a published certificate, and two are shown as Pending with a certificate in testing and available on request. The company describes itself as a newer platform, in those words, and this site repeats the phrase rather than upgrading it.

This row is a paid row, and the arrangement behind it is not hidden in a footnote. The full account is on this row is a paid row, here is the arrangement.